ArticleJournal for immunotherapy of cancer2023

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.

Madeline Dahut et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.